The α4β7 blockade with vedolizumab is effective in prevention of graft vs. host disease using a xenogeneic mouse model

Senthilnathan Palaniyandi; Reena Kumari; Ethan Strattan; Timothy Huang; Jing Du; Natalya Hakim; Melissa V. Kesler; Gerhard C. Hildebrandt

doi:10.1002/ajh.25678

The α4β7 blockade with vedolizumab is effective in prevention of graft vs. host disease using a xenogeneic mouse model

Senthilnathan Palaniyandi, Reena Kumari, Ethan Strattan, Timothy Huang, Jing Du, Natalya Hakim, Melissa V. Kesler, Gerhard C. Hildebrandt

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English
Pages (from-to)	E39-E41
Journal	American Journal of Hematology
Volume	95
Issue number	2
DOIs	https://doi.org/10.1002/ajh.25678
State	Published - Feb 1 2020

Bibliographical note

Funding Information:
This study was funded by TAKEDA Pharmaceuticals U.S.A through IISR grant (SP and GCH). This research was supported by the Biospecimen Procurement & Translational Pathology Shared Resource Facility and Flow Cytometry and Cell Sorting Core Facility: Supported by the Markey Cancer Center and an NCI Center Core Support Grant (P30CA177558).

Funding Information:
This study was funded by TAKEDA Pharmaceuticals U.S.A through IISR grant (SP and GCH). This research was supported by the Biospecimen Procurement & Translational Pathology Shared Resource Facility and Flow Cytometry and Cell Sorting Core Facility: Supported by the Markey Cancer Center and an NCI Center Core Support Grant (P30CA177558).

Funding

This study was funded by TAKEDA Pharmaceuticals U.S.A through IISR grant (SP and GCH). This research was supported by the Biospecimen Procurement & Translational Pathology Shared Resource Facility and Flow Cytometry and Cell Sorting Core Facility: Supported by the Markey Cancer Center and an NCI Center Core Support Grant (P30CA177558). This study was funded by TAKEDA Pharmaceuticals U.S.A through IISR grant (SP and GCH). This research was supported by the Biospecimen Procurement & Translational Pathology Shared Resource Facility and Flow Cytometry and Cell Sorting Core Facility: Supported by the Markey Cancer Center and an NCI Center Core Support Grant (P30CA177558).

Funders	Funder number
Biospecimen Procurement & Translational Pathology Shared Resource Facility
IISR
Markey Cancer Center
Markey Cancer Center NCI
National Childhood Cancer Registry – National Cancer Institute	P30CA177558
Center for Outcomes Research and Evaluation, Yale School of Medicine
Takeda Pharmaceuticals U.S.A.
University of Kentucky Markey Cancer Center

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.25678

Cite this

@article{0e05411d6b664f518be825aa3ccfe3b2,

title = "The α4β7 blockade with vedolizumab is effective in prevention of graft vs. host disease using a xenogeneic mouse model",

author = "Senthilnathan Palaniyandi and Reena Kumari and Ethan Strattan and Timothy Huang and Jing Du and Natalya Hakim and Kesler, \{Melissa V.\} and Hildebrandt, \{Gerhard C.\}",

note = "Funding Information: This study was funded by TAKEDA Pharmaceuticals U.S.A through IISR grant (SP and GCH). This research was supported by the Biospecimen Procurement \& Translational Pathology Shared Resource Facility and Flow Cytometry and Cell Sorting Core Facility: Supported by the Markey Cancer Center and an NCI Center Core Support Grant (P30CA177558). Funding Information: This study was funded by TAKEDA Pharmaceuticals U.S.A through IISR grant (SP and GCH). This research was supported by the Biospecimen Procurement \& Translational Pathology Shared Resource Facility and Flow Cytometry and Cell Sorting Core Facility: Supported by the Markey Cancer Center and an NCI Center Core Support Grant (P30CA177558).",

year = "2020",

month = feb,

day = "1",

doi = "10.1002/ajh.25678",

language = "English",

volume = "95",

pages = "E39--E41",

number = "2",

}

TY - JOUR

T1 - The α4β7 blockade with vedolizumab is effective in prevention of graft vs. host disease using a xenogeneic mouse model

AU - Palaniyandi, Senthilnathan

AU - Kumari, Reena

AU - Strattan, Ethan

AU - Huang, Timothy

AU - Du, Jing

AU - Hakim, Natalya

AU - Kesler, Melissa V.

AU - Hildebrandt, Gerhard C.

N1 - Funding Information: This study was funded by TAKEDA Pharmaceuticals U.S.A through IISR grant (SP and GCH). This research was supported by the Biospecimen Procurement & Translational Pathology Shared Resource Facility and Flow Cytometry and Cell Sorting Core Facility: Supported by the Markey Cancer Center and an NCI Center Core Support Grant (P30CA177558). Funding Information: This study was funded by TAKEDA Pharmaceuticals U.S.A through IISR grant (SP and GCH). This research was supported by the Biospecimen Procurement & Translational Pathology Shared Resource Facility and Flow Cytometry and Cell Sorting Core Facility: Supported by the Markey Cancer Center and an NCI Center Core Support Grant (P30CA177558).

PY - 2020/2/1

Y1 - 2020/2/1

UR - https://www.scopus.com/pages/publications/85076402849

UR - https://www.scopus.com/inward/citedby.url?scp=85076402849&partnerID=8YFLogxK

U2 - 10.1002/ajh.25678

DO - 10.1002/ajh.25678

M3 - Letter

C2 - 31724186

AN - SCOPUS:85076402849

SN - 0361-8609

VL - 95

SP - E39-E41

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 2

ER -

The α4β7 blockade with vedolizumab is effective in prevention of graft vs. host disease using a xenogeneic mouse model

Bibliographical note

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this